COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01071460
Recruitment Status : Completed
First Posted : February 19, 2010
Last Update Posted : November 9, 2012
Information provided by:
Provascular GmbH

Brief Summary:

Purpose of this registry is to determine the efficacy and safety of the self-expanding, extra flexible FlexStent in patient with superficial femor/popliteal artery disease.

The stent has been developed to cope with the extreme requirements of the femoral artery/knee artery and is approved for usage at humans (EC-certified). It is designed to treat narrows of the femoral- and knee artery.

100 patients at 5 German hospital shall be enrolled. After stent implantation follow-up visits at 6 and 12 month take place.

Condition or disease Intervention/treatment Phase
Efficacy of the Study Device Device: FlexStent Femoropopliteal Self-Expanding Stent System Phase 3

Detailed Description:

Peripheral arterial disease (PAD) represents a major challenge to physicians in treating the Superficial Femoral (SFA) and Popliteal arteries. These arteries represent a harsh environment for any endovascular device. This disease is characterized by long occlusions with relatively low flow and with the vessels exposed to enormous mechanical stress. During flexing of the knee, the SFA/Popliteal arteries can bend, rotate, elongate and compress dramatically. An ideal stent designed for use in the SFA/Popliteal arteries would offer great ranges of movement while adequately supporting the arteries.

The FlexStent® stent provides a great range of motions for a highly flexible femoral artery while adequately supporting the vessel. The intended use for the FlexStent® stent is for the treatment of symptomatic femoropopliteal disease, primarily for atherosclerotic de novo native superficial femoral artery lesions.

The intent of this clinical registry is to demonstrate the efficacy and safety of the FlexStent® stent in patients with superficial femoral/ popliteal artery disease.

Hypothesis: the FlexStent® will be safe and efficacious in treating SFA/popliteal artery diseases.

Primary object: evaluation of efficacy of the FlexStent® measured by the in-stent restenosis using DUS following treatment, 6 and 12 MFU visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The FlexStent-Registry, Evaluation of Efficacy and Safety of the FlexStent Femoropopliteal Self-Expanding Stent System
Study Start Date : November 2009
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Arm Intervention/treatment
SFA Stenting Device: FlexStent Femoropopliteal Self-Expanding Stent System

Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy

Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:

  • Contralateral retrograde common femoral cross-over access or antegrade access
  • Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion
  • Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis
  • Deployment of an appropriately sized FlexStent® to cover target lesion
  • Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter
  • Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications

Primary Outcome Measures :
  1. in-stent binary restenosis using DUS [ Time Frame: after treatment, at 6 and 12 MFU ]

Secondary Outcome Measures :
  1. technical success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30% [ Time Frame: at 6 and 12 MFU ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects, male or female, must be between the ages of 35 to 85 years inclusive at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test at Screening.
  • Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol.
  • Rutherford Classification Category 2-4
  • Single de novo lesion in the superficial femoro/popliteal artery
  • Disease segment length ≤150mm

    ->70% diameter stenosis and occlusion

  • Patent ipsilateral iliac artery
  • Patent ipsilateral popliteal artery and at least 1 patent tibial artery in continuity to ankle
  • Target reference vessel diameter 3.5-7.5 mm

Exclusion Criteria:

  • Target lesion previously treated with a stent or surgery.
  • Rutherford Classification Category 0,1,5 or 6.
  • Inability to tolerate antithrombotic or antiplatelet therapies.
  • Pregnancy.
  • Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
  • Serum creatinine > 2.5 mg/dL.
  • Myocardial infarction or stroke within 90 days of enrollment.
  • Hypercoagulable state.
  • Uncontrollable hypertension.
  • Patients currently enrolled in any other clinical trial(s).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01071460

Layout table for location information
Herz-Zentrum Bad Krozingen Abteilung Angiologie
Bad Krozingen, Germany, 79189
Jüdisches Krankenhaus Berlin, Gefäßzentrum
Berlin, Germany, 13347
Park-Krankenhaus Leipzig
Leipzig, Germany, 04289
Sponsors and Collaborators
Provascular GmbH
Layout table for investigator information
Principal Investigator: Dierk Scheinert, Professor Park-Krankenhaus Leipzig
Layout table for additonal information
Responsible Party: Dierk Scheinert, MD, Park Krankenhaus Leipzig Identifier: NCT01071460    
Other Study ID Numbers: Prov 01-2009
147-2009-06072009 ( Other Identifier: Ethic Committee at the University of Leipzig, Germany )
First Posted: February 19, 2010    Key Record Dates
Last Update Posted: November 9, 2012
Last Verified: November 2012
Keywords provided by Provascular GmbH: